Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Please note: We are reviewing Western blot images included in the antibody testing data in our catalog, including those provided by third parties. Unless expressly labeled or annotated as “raw-unedited”, Western blot images included in the antibody testing data in our catalog may have been edited, optimized or otherwise adjusted for presentation.
Reconstitute with sterile PBS to a final concentration of 0.5 mg/mL.
The Leucine-rich repeat transmembrane neuronal proteins (LRRTMs) are differentially expressed in the nervous system and were recently found to instruct presynaptic and mediate postsynaptic glutamatergic differentiation, with LRRTM1 and LRRTM2 most potent at inducing presynaptic differentiation. Recent evidence suggests that LRRTM3 promotes the processing of amyloid-precursor protein (APP) by the beta-secretase BACE, leading to the proteolytic production of the A-beta42 peptide that is the main component of amyloid plaques. Furthermore, LRRTM3 maps to a region of chromosome 10 linked to both late-onset Alzheimer's disease (AD) and elevated plasma A-beta42 levels, suggesting that LRRTM3 is a functional and positional candidate gene for AD.
仅用于科研。不用于诊断过程。未经明确授权不得转售。